Prospect News: News for Onyx Pharmaceuticals Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with O > Issuers starting with O, CV only > All stories on Onyx Pharmaceuticals Inc. > Stories on Onyx Pharmaceuticals Inc., CV only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Onyx Pharmaceuticals Inc.

11/19/2013	CVLM	Onyx Pharmaceuticals calls all $35 million of 4% convertibles due 2016
8/26/2013	CV	Market Commentary: Tesla convertibles move up in line before shares pare gains; Onyx 7 points over parity
7/1/2013	CV	Market Commentary: Upcoming holiday weighs on liquidity in convertibles market; Intel active; Onyx rises
7/23/2012	CV	Market Commentary: Convertibles mostly quiet: Kodak drops sharply after negative ruling; Onyx adds on hedge
7/2/2012	CV	Market Commentary: Lincare jumps on hedged basis on Linde takeout; Amylin up outright on Bristol-Myers deal
6/22/2012	CV	Market Commentary: Patriot Coal continues to weaken; Onyx extends gains; Royal Gold slips in line; K-V drops
6/21/2012	CV	Market Commentary: Convertibles hold up despite slide in shares; Onyx surges on drug panel backing; AMR retraces 60
6/20/2012	CV	Onyx convertible eyed after cancer drug gets backing of FDA panel
11/29/2011	CV	Market Commentary: AMR collapses after bankruptcy filing; Transocean Cs improve; Onyx seen lower on hedge
7/27/2010	CV	Market Commentary: Gilead opens higher, comes in; Onyx, ViroPharma in trade; AGCO in line; A&P bounces around
7/8/2010	CV	Market Commentary: Convertibles 'better to buy'; Transocean paper sees strength; Hologic improves; Onyx quiet
10/12/2009	CV	Market Commentary: Convertibles mostly quiet; Cameron, Nabors edge higher as oil rises; US Airways, AMR firm
8/7/2009	CV	Market Commentary: Onyx, Rayonier price rich, jump; D.R. Horton up with sector; Cubist gets pre-conference boost
8/7/2009	CV	New Issue: Onyx prices $200 million of seven-year convertibles at 4%, up 30%
8/6/2009	CV	Onyx prices $200 million seven-year convertibles to yield 4%, up 30%
8/6/2009	CV	Market Commentary: Onyx stays afloat in gray; Rayonier quiet; Alexandria, Virgin Media gain with earnings
8/5/2009	CV	Market Commentary: Onyx up in gray; UAL boosted by oil, report; Transocean drops on results; Rayonier plans deal
8/4/2009	CV	Onyx talks $200 million of seven-year convertibles at 4%-4.5%, up 20%-25% for Thursday
8/4/2009	CV	Market Commentary: Hologic higher on earnings, forecast; Vale, Human Genome gain after upgrades; Onyx plans deal
6/18/2007	CV	Onyx Pharmaceuticals files automatic shelf registration
5/30/2006	BTCVHY	Onyx Pharmaceuticals files $300 million shelf
1/20/2005	CV	Onyx Pharmaceuticals files $250 million shelf

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.